Skye Salud Advances to Phase 2 Clinical Evaluation in Mexico
Event summary
- Skye Salud, an AI-powered medical evidence platform, advances to Phase 2 clinical evaluation in Mexico after successful Phase 1 rheumatology testing.
- Phase 2 will expand testing into primary care use cases, assessing the platform across a broader range of clinical topics and physician information needs.
- The initiative combines BEN's enterprise-grade AI capabilities, Grupo Skye's leadership in AI innovation across Latin America, and KNOBLOCH Information Group's trusted relationships within Mexico's healthcare community.
- Mexico represents one of the largest healthcare markets in Latin America, creating a significant opportunity to evaluate AI-enabled access to trusted medical evidence at scale.
The big picture
This advancement reflects BEN's broader strategy of developing governed, enterprise-grade AI solutions for regulated industries where accuracy, transparency, accountability, and human engagement are critical. The initiative aims to improve access to clinical information across healthcare settings in Mexico and Latin America, leveraging trusted medical literature and clinical guidelines.
What we're watching
- Market Expansion
- Whether Skye Salud can successfully scale its AI-powered medical evidence platform across broader healthcare settings in Mexico and Latin America.
- Regulatory Considerations
- How regulatory developments may impact the future deployment and commercialization of the platform within healthcare settings.
- Commercialization Opportunities
- The pace at which BEN, Grupo Skye, and KNOBLOCH Information Group can explore opportunities to broaden clinical coverage and expand Spanish-language medical content.